findmyKOL

Michael Boland, MD

Enriched profile

Assistant Chief Medical Information Officer, Mass General Brigham; Medical Director of Practice Innovation, Ophthalmology, Massachusetts Eye and Ear; Associate Professor of Ophthalmology, Harvard Medical School · Mass General Brigham

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyOphthalmologyFocusGlaucoma
Active KOLLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Michael Boland is Assistant Chief Medical Information Officer, Mass General Brigham; Medical Director of Practice Innovation, Ophthalmology, Massachusetts Eye and Ear; Associate Professor of Ophthalmology, Harvard Medical School at Mass General Brigham. OpenAlex indexes 283 publications with 5,792 citations (h-index 39); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Michael V. Boland, MD, is Assistant Chief Medical Information Officer, Mass General Brigham. The public record shows 283 publications with 5,792 citations (h-index 39), centered on Glaucoma. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 9 companies.

  • Most recent indexed publication: 2025 · Journal of glaucoma
  • Top research focus: Glaucoma
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma1 trialComa1 trial

Research focus

OpenAlex concept fingerprint
Glaucoma

Drugs & molecules

across trials, industry payments and publications
Durystageneric · BimatoprostClinical trials—Industry payments11Publications—

Works with

trial sponsors and companies reporting payments
Carl Zeiss Meditec, Inc.Clinical trials—Industry payments14Allergan, Inc.Clinical trials—Industry payments8Abbvie Inc.Clinical trials—Industry payments5Topcon Medical Systems, Inc.Clinical trials—Industry payments5Topcon Healthcare, Inc.Clinical trials—Industry payments2Alcon Vision LLCClinical trials—Industry payments1Carl Zeiss Meditec USA, Inc.Clinical trials—Industry payments1Janssen Research & Development, LLCClinical trials—Industry payments1Johns Hopkins UniversityClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
283publications

Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.

5,792citations

Total citations across indexed works.

39h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    88%
    Prostaglandin Analog37.1%
    Latanoprost96%Travoprost2%Lumigan2%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor22.3%
    Dorzolamide-Timolol76%Dorzolamide Hcl19%Acetazolamide Er6%
    Part D<11 patients

    + 5 more classes in this area

  • Cardiovascular

    10.4%
    Beta blocker10.4%
    Timolol Maleate100%
    Part D≥59 patients
  • Musculoskeletal

    0.9%
    Cyclooxygenase Inhibitor0.9%
    Ketorolac Tromethamine100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)24.9% facility · 75.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/cv/michael-boland-md-ab48792a

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/profile/Michael-Boland-2

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
  • ResearchGate

    researchgate.net/profile/Michael-Boland-6

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Other

    talkingaboutglaucoma.com/guests/michael-boland

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →talkingaboutglaucoma.com ↗
  • Doximity

    Doximity profile (auth-walled, corroborated via SERP snippet as Boston, MA ophthalmology)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.